Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:AVRO

AVROBIO (AVRO) Stock Price, News & Analysis

AVROBIO logo

About AVROBIO Stock (NASDAQ:AVRO)

Advanced Chart
Remove Ads

Key Stats

Today's Range
$1.38
$1.44
50-Day Range
$1.40
$18.24
52-Week Range
$0.88
$1.65
Volume
206,800 shs
Average Volume
269,831 shs
Market Capitalization
$62.85 million
P/E Ratio
2.03
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

AVROBIO, Inc., a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1 and 3; AVR-RD-01, which is in phase 2 clinical trials for the treatment of Fabry disease; and AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Remove Ads
Receive AVRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AVROBIO and its competitors with MarketBeat's FREE daily newsletter.

AVRO Stock News Headlines

Trump’s Great Society
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
L'action TECX atteint un sommet sur 52 semaines à 53,41$
See More Headlines

AVRO Stock Analysis - Frequently Asked Questions

AVROBIO, Inc. (NASDAQ:AVRO) issued its quarterly earnings data on Thursday, November, 4th. The company reported ($9.00) earnings per share for the quarter, hitting analysts' consensus estimates of ($9.00).

AVROBIO shares reverse split on Thursday, June 20th 2024. The 1-12 reverse split was announced on Thursday, June 20th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 20th 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

AVROBIO (AVRO) raised $75 million in an initial public offering on Thursday, June 21st 2018. The company issued 4,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, Cowen and Wells Fargo Securities acted as the underwriters for the IPO and Wedbush Securities was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that AVROBIO investors own include Meta Platforms (META), NVIDIA (NVDA), CymaBay Therapeutics (CBAY), Broadcom (AVGO), CrowdStrike (CRWD), Advanced Micro Devices (AMD) and Adobe (ADBE).

Company Calendar

Last Earnings
11/04/2021
Today
3/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:AVRO
Fax
N/A
Employees
13
Year Founded
N/A

Profitability

Trailing P/E Ratio
2.03
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$12.16 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$2.13 per share
Price / Book
0.66

Miscellaneous

Free Float
40,764,000
Market Cap
$62.85 million
Optionable
Optionable
Beta
1.23
7 Top Nuclear Stocks To Buy Now Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:AVRO) was last updated on 3/29/2025 by MarketBeat.com Staff
From Our Partners